DBV Technologies S.A. (DBVT)
Market Cap | 269.13M |
Revenue (ttm) | 9.73M |
Net Income (ttm) | -75.79M |
Shares Out | 199.36M |
EPS (ttm) | -0.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 137,989 |
Open | 1.38 |
Previous Close | 1.38 |
Day's Range | 1.33 - 1.40 |
52-Week Range | 1.08 - 3.43 |
Beta | 1.24 |
Analysts | Buy |
Price Target | 2.92 (+116.3%) |
Earnings Date | Mar 2, 2023 |
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin... [Read more]
Financial Performance
In 2021, DBVT's revenue was 5.71 million, a decrease of -49.38% compared to the previous year's 11.28 million. Losses were -97.81 million, -38.70% less than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is $2.92, which is an increase of 116.30% from the latest price.
News

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated Information Montrouge, France, January 23, 2023

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study
The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
Montrouge, France, December 23, 2022

DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, November 22, 2022

DBV Technologies to Highlight New Clinical Data at ACAAI 2022
Montrouge, France, November 9, 2022

DBV Technologies Reports Third Quarter Financial Results and Business Update
Montrouge, France, November 3, 2022

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
Montrouge, France, October 31, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT
NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of DBV Technologies S.A. - DBVT
New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors ...

DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
Montrouge, France, October 3, 2022

DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold
DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA.

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
Montrouge, France, September 21, 2022

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years
Montrouge, France, September 7, 2022

DBV Technologies to Present at Upcoming Investor Conferences
Montrouge, France, September 2, 2022

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.

DBV Technologies Reports Second Quarter 2022 Financial Results
Montrouge, France, August 1, 2022

DBV Technologies to Participate in Upcoming EAACI 2022 Congress
Montrouge, France, June 28, 2022

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
Montrouge, France, June 16, 2022

Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?
Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

DBV Technologies Announces Private Placement Financing of $194 Million
Montrouge, France, June 9, 2022

HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?
HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage ...

DBV Technologies Shares Jump On Positive Data From Peanut Allergy Trial In Toddlers
DBV Technologies SA's (NASDAQ: DBVT) pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years met its primary endpoint. Viaskin Peanut demonstrated a stat...

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Montrouge, France, June 7, 2022

DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting
Montrouge, France, May 12, 2022

DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)
Montrouge, France, May 5, 2022